CN108498756A - Drug and preparation method thereof for preventing and/or treating Parkinson's disease - Google Patents

Drug and preparation method thereof for preventing and/or treating Parkinson's disease Download PDF

Info

Publication number
CN108498756A
CN108498756A CN201810366621.XA CN201810366621A CN108498756A CN 108498756 A CN108498756 A CN 108498756A CN 201810366621 A CN201810366621 A CN 201810366621A CN 108498756 A CN108498756 A CN 108498756A
Authority
CN
China
Prior art keywords
weight
parts
disease
radix
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810366621.XA
Other languages
Chinese (zh)
Inventor
徐洋
魏仁荣
林同香
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Hospital of Traditional Chinese Medicine
Original Assignee
Guangdong Hospital of Traditional Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Hospital of Traditional Chinese Medicine filed Critical Guangdong Hospital of Traditional Chinese Medicine
Priority to CN201810366621.XA priority Critical patent/CN108498756A/en
Publication of CN108498756A publication Critical patent/CN108498756A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention discloses a kind of drug for preventing and/or treating Parkinson's disease, and active ingredient is by following parts by weight material composition：8~15 parts by weight of curcuma zedoary, 15~25 parts by weight of Glabrous Sarcandra Herb, 15~25 parts by weight of Asian puccoon, 10~20 parts by weight of radix paeoniae rubra, 15~25 parts by weight of smilax, 15~25 parts by weight of dark plum, 15~25 parts by weight of Radix Glycyrrhizae, 15~25 parts by weight of Radix Angelicae Sinensis, 15~25 parts by weight of Rhizoma Chuanxiong, 15~25 parts by weight of Radix Rehmanniae.The drug of present invention prevention and/or treatment Parkinson's disease disease can improve the motor function of rat model, reduce the pathological change of brain striatum and substantia nigra compacta, such as reduce DA serotonergic neuron cell loss, and then achieve the purpose that treatment Parkinson's disease.

Description

Drug and preparation method thereof for preventing and/or treating Parkinson's disease
Technical field
The present invention relates to a kind of Chinese medicine compositions, and in particular to a kind of Chinese medicine for preventing and/or treating Parkinson's disease Composition.
Background technology
With rapid economic development, astogeny progress faster and severe environmental pollution, the trouble of Parkinson's disease in elderly population Sick rate rises situation in apparent, and result of study is shown, in current and expected future, Chinese Parkinson's disease number of patients will in for a period of time Account for global half or so：Chinese Parkinson's disease case load is about 1.99 × 106 within 2005, about 4.10 × 106, the whole world；2030 Year Chinese Parkinson's disease case load about 4.94 × 106, about 8.67 × 106, the whole world.Parkinson's disease (Parkinson ' s Disease, PD) it is common neurodegenerative disease, most important pathological change is substantia nigra of midbrain dopamine The denaturation of (dopamine, DA) serotonergic neuron is dead, and it includes that progressive bradykinesia, flesh are strong that clinic, which is mainly characterized by dyskinesia, Directly, static tremor and posture abnormal gait etc., additionally can be with a large amount of non-motor symptoms, such as hyposphresia, constipation, suppression Strongly fragrant, sleep disturbance etc..With the progress of the course of disease, motor symptoms and non-motor symptoms gradually aggravate, until end-stage disease is often transported Dynamic complication, including curative effect of medication decline, " on-off " phenomenon, unusual fluctuation disease etc..End-stage disease patient Chang Yin disequilibriums, tumble, Freezing of gait, dysphagia and aphasis etc. cause life that can not take care of oneself or even long-term bed, quality of life degradation. Drug therapy is the main means of clinical treatment Parkinson's disease, and can only be risen by the first-line treatment drug of representative of levodopa To symptom effect is alleviated, such drug is taken for a long time it may also occur that the side effects such as unusual fluctuation disease.Traditional Chinese medicine is in prevention geriatric disease Aspect has abundant theory and practice experience and potential advantage.Therefore, development and exploitation can delay Parkinson's disease process, Improving the new Chinese medicine of patients ' life quality will have important practical significance and wide application prospect.
Although the pathogenesis to PD has numerous studies, the precise mechanism of DA serotonergic neuron death is not clear.Mesh It is preceding it is believed that PD be not single factors cause a disease, possible many factors are participated.Inherent cause can be such that susceptibility increases Add, under environmental factor and aging collective effect, by oxidative stress, mitochondrial function failure, toxicity of excitatory amino acid and The mechanism such as Apoptosis cause black substance DA serotonergic neurons to be largely denaturalized loss, cause to fall ill.Largely studies have shown that with small glue The nerve immunity inflammation that cell plastid activation, proliferation of astrocytes and lymphocytic infiltration are characterized rises in PD pathogenesis Highly important effect, it may be possible to the driving force of DA serotonergic neuron progressive denaturation.Therefore, above-mentioned immune anti-to prevent or lower Therapy for the purpose of answering, it may be possible to PD progression of disease be prevented even to terminate the effective means of pathogenesis.
The patent application of 105233150 A of Publication No. CN discloses a kind of Chinese medicine composition for treating psoriasis, the group It is to contain preparation made of following raw material to close object；10 parts by weight of curcuma zedoary, 20 parts by weight of Glabrous Sarcandra Herb, 20 parts by weight of Asian puccoon, 15 parts by weight of radix paeoniae rubra, 20 parts by weight of smilax, 20 parts by weight of dark plum, 10 parts by weight of Radix Glycyrrhizae, 10 parts by weight of Radix Angelicae Sinensis, 10 weight of Rhizoma Chuanxiong Measure part, 20 parts by weight of Radix Rehmanniae.The prescription of the patent application have the function of it is clearing heat and detoxicating, promoting blood circulation and removing blood stasis, for treating psoriasis It is curative for effect；With expelling wind and clearing away heat, dehumidification swelling, promoting blood circulation and removing obstruction in channels, closed for treating psoriasis arthropathica and rheumatoid Section is scorching, curative for effect.
Currently, silver bits health piece is clinically applied as the drug for the treatment of psoriasis, there is not yet being applied to prevention The research of PD is reported.
Invention content
In order to solve the above-mentioned technical problem, present invention firstly provides a kind of for preventing and/or treating Parkinson's disease Drug, active ingredient is by following parts by weight material composition：8~15 parts by weight of curcuma zedoary, 15~25 parts by weight of Glabrous Sarcandra Herb, Asian puccoon 15 ~25 parts by weight, 10~20 parts by weight of radix paeoniae rubra, 15~25 parts by weight of smilax, 15~25 parts by weight of dark plum, 15~25 weight of Radix Glycyrrhizae Measure part, 15~25 parts by weight of Radix Angelicae Sinensis, 15~25 parts by weight of Rhizoma Chuanxiong, 15~25 parts by weight of Radix Rehmanniae.
In some embodiments, its active ingredient of said medicine is preferably by following parts by weight material composition：10 weight of curcuma zedoary Measure part, 20 parts by weight of Glabrous Sarcandra Herb, 20 parts by weight of Asian puccoon, 15 parts by weight of radix paeoniae rubra, 20 parts by weight of smilax, 20 parts by weight of dark plum, sweet Careless 10 parts by weight, 10 parts by weight of Radix Angelicae Sinensis, 10 parts by weight of Rhizoma Chuanxiong, 20 parts by weight of Radix Rehmanniae.
According to another aspect of the present invention, the preparation method for additionally providing said medicine, includes the following steps：
(1) it weighs smilax and crushed 80 mesh sieve, it is spare；
(2) curcuma zedoary, Glabrous Sarcandra Herb, Asian puccoon, radix paeoniae rubra, dark plum, Radix Glycyrrhizae, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Rehmanniae drying medicine materical crude slice are weighed, is carried with water Take decoction three times, for the first time plus 10~12 times are measured water, are extracted 2 hours；Second and third time is respectively plus 8~10 times of amount water, extraction 1 are small When, filtering merges extracting solution, discards residue；
(3) thick paste for stopping that heat survey proportion is 1.10~1.20 is concentrated under reduced pressure, is cooled to room temperature, ethyl alcohol is added to alcohol content 70%, it places for 24 hours, filtering, recycles ethyl alcohol, concentration surveys the thick paste that proportion is 1.30~1.40 to heat；
(4) it takes lactose, starch, dextrin to be uniformly mixed with the thick paste of step (3), dry, pulverize 80 mesh sieve, be added hard The smilax powder of fatty acid magnesium and step (1) is uniformly mixed, conventionally prepares piece agent；Wherein, the lactose, starch Addition with dextrin is the 32.67% of thick paste weight, and the weight ratio between lactose, starch and dextrin is 1:2:6, the tristearin The addition of sour magnesium is the 0.67% of thick paste weight.
According to another aspect of the present invention, said medicine is also provided and is preparing prevention and/or treatment Parkinson's disease disease Drug in application be specifically by the present invention for preventing and/or treating the Chinese medicine composition of Parkinson's disease according to preceding It states preparation method and prepares piece agent, the instructions of taking of the tablet is：5 tablets once by adult, and 3 times a day (it is each primary in the morning, afternoon and evening, after the meal Take), 7 days as a course for the treatment of.
The drug of present invention prevention and/or treatment Parkinson's disease disease can improve the motor function of rat model, reduce The pathological change of brain striatum and substantia nigra compacta such as reduces DA serotonergic neuron cell loss, and then reaches treatment Parkinson's disease Purpose.
Description of the drawings
Fig. 1 is the influence for the circling behavior that drug of the present invention induces apomorphine；
Fig. 2 is influence of the drug of the present invention to PD rat substantia nigra TH positive neurons；
Fig. 3 is influence of the drug of the present invention to PD rat substantia nigra TH positive neurons；
Fig. 4 is the influence that drug of the present invention expresses PD rat substantia nigra TH mRNA.
Specific implementation mode
With reference to embodiment and attached drawing, the present invention is described in further detail.
Raw materials of traditional Chinese medicinal materials is weighed according to following parts by weight：10 parts by weight of curcuma zedoary, 20 parts by weight of Glabrous Sarcandra Herb, 20 weight of Asian puccoon Part, 15 parts by weight of radix paeoniae rubra, 20 parts by weight of smilax, 20 parts by weight of dark plum, 10 parts by weight of Radix Glycyrrhizae, 10 parts by weight of Radix Angelicae Sinensis, Rhizoma Chuanxiong 10 Then tablet is made in parts by weight, 20 parts by weight of Radix Rehmanniae as follows (each tablet fill weights are 0.5g)：
(1) it weighs smilax and crushed 80 mesh sieve, it is spare；
(2) curcuma zedoary, Glabrous Sarcandra Herb, Asian puccoon, radix paeoniae rubra, dark plum, Radix Glycyrrhizae, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Rehmanniae drying medicine materical crude slice are weighed, is carried with water Take decoction three times, for the first time plus 10~12 times are measured water, are extracted 2 hours；Second and third time is respectively plus 8~10 times of amount water, extraction 1 are small When, filtering merges extracting solution, discards residue；
(3) thick paste for stopping that heat survey proportion is 1.10~1.20 is concentrated under reduced pressure, is cooled to room temperature, ethyl alcohol is added to alcohol content 70%, it places for 24 hours, filtering, recycles ethyl alcohol, concentration surveys the thick paste that proportion is 1.30~1.40 to heat；
(4) it takes lactose, starch, dextrin to be uniformly mixed with the thick paste of step (3), dry, pulverize 80 mesh sieve, be added hard The smilax powder of fatty acid magnesium and step (1) is uniformly mixed, conventionally prepares piece agent；Wherein, the lactose, starch Addition with dextrin is the 32.67% of thick paste weight, and the weight ratio between lactose, starch and dextrin is 1:2:6, the tristearin The addition of sour magnesium is the 0.67% of thick paste weight.
In order to prove the curative effect of the present invention, it is real that tablet obtained above (i.e. following silver bits health pieces) is subjected to following drug effects It tests.
One, silver bits health piece is to the neuroprotection of 6-OHDAPD rats and the experiment of neuroinflamation inhibiting effect
1 materials and methods
1.1 experiment material
1.1.1 experimental animal
SPF grades of male SD rats 36,220~250g of weight are purchased from Beijing dimension limited public affairs of tonneau China's experimental animal technology Department.Rat feeding condition：24 ± 1 DEG C, humidity 40-80% of room temperature, illumination 12h light and shades alternating, free water, feed.Before experiment Confirm circling behavior without exception through the detection of conventional behaviouristics.Experimentation abides by experimental animal criterion related with protection.
1.1.2 key instrument
Desktop digital display stereotaxic apparatus (RWD Life Science Co., Ltd. Shenzhen)；10 μ L micro-sampling pins (on Hai Gaoge Trade Co., Ltd.s)；Slicer:LEICA RM2235；OLYMPUS inverted microscopes:NiKon ECLIPSE TS100；PCR instrument；Fluorescence quantitative PCR instrument；Centrifuge；Low temperature refrigerator (Sanyo, Japan), ultra low temperature freezer (U.S. water chestnut, China), Homogenizer (BD, the U.S.), table-type high-speed refrigerated centrifuge (Eppendorf companies, Germany), RT-PCR instrument, electrophoretic apparatus (Bio- Rad companies, the U.S.), 7500 sequence fluorescence quantitative PCR instruments (applying Biosystems, the U.S.) and PM-30 inverted microscopes-meter Calculation machine image analysis system (Olympus, Japan).
1.1.3 reagent
6-OHDA hydrobromates (6-hydroxydopamine hydrobromide, 6-OHDA), apomorphine (Apomorphine, APO) and L-AA (L-AscorbicAcid) are purchased from Sigma companies；Tyrosine hydroxylase (Tyrosine hydroxylase, TH) antibody, Iba-1 antibody (Abcam companies)；The efficient immunohistochemistry secondary antibody examination of instant Agent box (You Ningwei companies)；RNA Reverse Transcriptase kits (Promega companies)；Primer synthesizes (Hua Da gene)；SYBR Green Supermix (Bio-rad companies)；
1.1.4 drug solution preparing
According to《Herbal pharmacology experimental methodology》Regulation, the selection of rat dosage is according to equivalent between different genera animal The direct convert formula of dosage calculates, and daily silver considers health piece 7.5g (5 × 3 times × 0.5g) to be worth doing to adult, and rat uses medicament Amount is 6 times of adult, takes the silver bits health piece addition distilled water to be fully suspended and is configured to every milliliter containing 0.075g pieces weight Suspension, 4 DEG C save backup.
1.2 experimental method
1.2.1 6-OHDA induces the preparation of PD models
All rats routine feeding under identical conditions, preoperative 12h fasting.Test group of animals is with 1% yellow Jackets Head is fixed on stereotaxic instrument, routine disinfection by solution (40mg/Kg) intraperitoneal injection of anesthesia, conventional preserved skin, cuts scalp And subcutaneous tissue, blunt separation skull outer membrane, fully exposure bregma and right side skull.According to rat written by Paxinos＆Watson Naoliqing capsule collection of illustrative plates determines the coordinate of right side two injection points of corpus straitum.First point coordinates：Bregma 0.0mm, sagittal suture right side 3.2mm, Subdural space 7.0mm；Second point coordinates：1.2mm after bregma, sagittal suture right side 4.0mm, Subdural space 7.0mm.In above-mentioned choosing Fixed coordinate points bore cranium with miniature abrasive drilling, and the 6-OHDA of 5 μ g/ μ l (is dissolved in the life of 0.2%L- ascorbic acid with micro syringe In reason brine) 4 μ l are injected separately into above-mentioned 2 points of test group of animals, and injection speed is 1 μ l/min, notes Bi Liuzhen 10min, the withdraw of the needle Speed is 1mm/min, to prevent liquid medicine spill.Scalp is routinely sutured after the withdraw of the needle, art finishes 100,000 u/100g of intraperitoneal injection penicillin. Sham-operation group is in 2 points of injection 0.2%L- ascorbic acid physiological saline, the 2 μ l of above-mentioned right side corpus straitum, the remaining same experimental group of processing. Each group animal routine feeding under same environment after revival.
1.2.2 grouping and administration
Rat is randomly divided into sham-operation group (12), model group (12), silver bits health piece treatment by random digits table Group (12), totally 3 groups.Start within 3 days before modeling preventive administration, daily 1 time, silver bits health piece is given by Yin Xiekangpian treatment groups (0.75g pieces weight/kg) gavage, model group and sham-operation group give equal dosage distilled water gavage, and continuous gavage is administered 8 weeks.It is used Dosage converts to obtain all in accordance with human body dosage.
1.3 circling behaviors detect
Respectively the 2nd, 4,6 and the 8th week after surgery in neck be subcutaneously injected apomorphine (0.5mg/kg), induce rat to be good for The single direction rotation behavior of side.5min starts counting up rotating cycle after apomorphine injection, when animal rotates with strong side forelimb or after Limb is fulcrum, and body ring is bent, end to end to rotate in place, with sample action of looking for food.It is rotated by 360 ° to be primary, keeping count 30min.
It is prepared by 1.4 materials and sample
For each group rat after 3% yellow Jackets (1.5ml/kg) intraperitoneal injection of anesthesia, every group randomly selects 6, carries out Saturating heart perfusion, takes cerebral tissue to be measured for immunohistochemistry；Every group 6 only broken end takes brain after anesthesia, on ice (the damage of stripping right side Side) midbrain and corpus straitum enter in EP pipes, and liquid nitrogen flash freezer, -80 DEG C of refrigerators preserve, the expression for detecting TH mRNA.
1.5 Immunohistochemical detection
(1) 1. paraffin section routinely dewaxes to water.2. antigen retrieval：The high fire of microwave boils citrate buffer, cuts Piece immerses in buffer solution, and high fire 3min in microwave, cooling 5min, the above process in triplicate, carry out down after room temperature natural cooling The step of face.3. PBS is cleaned 3 times, every time 3 minutes.4. disappear enzyme：Endogenous peroxydase is eliminated with hydrogen peroxide, room temperature is incubated It educates 10 minutes.5. PBS is cleaned 3 times, every time 3 minutes.6. super confining liquid closing, is incubated at room temperature 10min.7. PBS is cleaned 3 times, 3 minutes every time.8. incubating primary antibody：It is diluted with antibody diluent, is put into moisture preservation box and is incubated at room temperature 20min, it is right that PBS feminine genders need to be set According to the control of, Sample Positive and Sample Negative control, needs to do antibody concentration gradient before doing in batches, find optimum condition.9. PBS is clear It washes 3 times, every time 3 minutes.10. incubating primary antibody amplification agent：Instant is incubated at room temperature 10 minutes.PBS is cleaned 3 times, every time 3 minutes.Incubate secondary antibody：Instant is incubated at room temperature 10 minutes.PBS is cleaned 3 times, every time 3 minutes.Diaminobenzidine (DAB) is aobvious Color：It is protected from light, develops the color 3 minutes under mirror.Tap water rinses, and haematoxylin is redyed 30 seconds, and tap water rinses, 0.5% hydrochloride alcohol point Change 10 seconds, PBS returns indigo plant.Dehydration：70% ethyl alcohol 1 time × 3 minutes, 95% ethyl alcohol 1 time × 3 minutes, 1 time × 3 points of absolute ethyl alcohol Clock, dimethylbenzene transparent 1 time × 3 minutes.Neutral gum mounting.
(2) quantitative analysis about immune image：Every rat randomly selects 5 slices, and every slice randomly selects 4 The visual field, in the same visual field area, same amplification factor acquires image under same background luminous intensity.With Image-Pro Plus 6.0 image analysis system software statistics positive cell quantities.
1.6. total tissue RNA extraction separation
1. moving to 100mg tissues with Liquid nitrogen precooler through in 180 DEG C of oven cooking cycles, 8 hours mortars, grinding sample is extremely It is powdered, liquid nitrogen is continuously added in process of lapping；Suitable Trizol cracking tissues are added and grind；3-5 points are placed at room temperature Clock moves to lysate in clean no enzyme microcentrifugal tube after to be liquefied.2. the chloroform 0.2ml of precooling is added, rapidly Firmly turn upside down mixing, stands 5 minutes on ice, and protein complexes is made all to crack, and centrifuges (4 DEG C, 13000g, 15 minutes). 3. drawing upper strata aqueous phase, another is transferred to without 400 μ l isopropanols in enzyme centrifuge tube, are added, is firmly turned upside down rapidly mixed Even, -20 DEG C stand 30 minutes, precipitate RNA.It centrifuges (4 DEG C, 13000g, 10 minutes), the visible a little white precipitate of tube bottom.4. going Supernatant is added 75% ethyl alcohol (now being matched with no enzyme water) of 1ml, impurity elimination is washed after the mixing that turns upside down, and places 5 minutes on ice.From The heart (4 DEG C, 7600g, 5 minutes).5. blotting ethyl alcohol as possible, dry 5 minutes at room temperature, waits for remaining ethyl alcohol volatilization completely extremely RNA precipitate is transparent, is eventually adding 20 μ l nuclease-free waters, dissolves RNA.
1.7 reverse transcription
The synthesis of cDNA is carried out according to the program in kit specification.4 μ l of example reaction system contain 2 μ gRNA and with Nuclease-free water is added to 5 μ l in 1 μ l of power traction object, and 70 DEG C are heated 5 minutes.It freezes immediately on ice at least 5 minutes, is added and reverses Record 15 μ l of mixture, brief centrifugation 10 seconds.Mixing after annealing is heated to 25 DEG C and is incubated 5 minutes, extends heating 1 hour to 42 DEG C, It is taken out after being cooled to 4 DEG C, -20 DEG C of preservations.
Reverse transcription mix is as follows：
1.8 Real Time-PCR analyses
Contain in the real time reaction system of 20 μ l：The universal SYBR Green supermix (2 ×) of 10 μ l, 5 μ l of upstream and downstream primer mixture (respective final concentration is 500nM), the 5 μ l of cDNA of 20 times of dilution.
96 orifice plates are covered with fluorescent quantitation special sealing membrane, are put into quantitative fluorescent PCR instrument after brief centrifugation, amplification 40 A cycle, denaturation, annealing, extension required temperature, time are respectively 95 DEG C of 30s, 60 DEG C of 30s, 72 DEG C of 90s.
β-Actin are used as reference gene, each sample replication 3 times.The relative quantity of mRNA is indicated with Ct values, average Relative expression quantity passes through 2- △ △ Ct ANALYSIS OF CALCULATINGs.
The primer sequence is as follows：
1.9 statistical procedures
Statistical analysis uses SPSS20.0 statistical analysis softwares.Measurement data meets normal distribution and uses mean ± standard deviation It indicatesMultigroup measurement data is more conform with condition and uses single factor design variance analysis, compares use two-by-two between group LSD methods, P ＜ 0.05 are that difference is statistically significant.
Two, interpretation of result
1. silver medal considers health piece to be worth doing to the ethological influence of PD rat nerves
Sham-operation group has no circling behavior.Compared with the model group same period, silver bits health piece treats 8 Zhou Houneng and is obviously improved PD The circling behavior (P ＜ 0.01) of rat.It is shown in Table 1 and Fig. 1.As a result prompt silver bits health piece can improve the drug-induced rotation of PD rats Turn abnormal behavior.
1 each group rat rotating cycle of table comparison (N=12)
Note：The * * P ＜ 0.01 compared with the model group same period.
2. silver medal considers influence of the health piece to PD rat substantia nigra TH positive neurons to be worth doing
The TH positive neuron quantity of rats in sham-operated group black substance is more.Compared with sham-operation group, on the right side of model group rats TH positive neuron quantity substantially reduces (P ＜ 0.01)；TH positive cell numbers and model group are brighter on the right side of silver bits health piece group It is aobvious to increase (P ＜ 0.05), but its TH positive cell number is still less than sham-operation group (P ＜ 0.01).It is shown in Table 2, Fig. 2 and Fig. 3.
2 each group rat substantia nigra TH positive cell quantities of table comparison (N=6)
Note：The ##P ＜ 0.01 compared with sham-operation group；The * P ＜ 0.05 compared with model group.
3. the influence that silver medal bits health piece expresses PD rat substantia nigra TH mRNA
Compared with sham-operation group, TH gene expressions reduce model group, and difference is statistically significant (P ＜ 0.01)；Silver bits health Piece group compared with model group, increase by TH gene expressions, and difference is statistically significant (P ＜ 0.01).It is shown in Table 3 and Fig. 4.
3 each group rat substantia nigra TH mRNA expression of table comparison (N=6)
Note：The ##P ＜ 0.01 compared with sham-operation group；The * * P ＜ 0.01 compared with model group.
Conclusion
Silver bits health piece can improve the movement disorder symptoms of rat model of Parkinson disease；Reduce substantia nigra compacta dopaminergic god It degenerates through member.
Above-described is only some embodiments of the present invention.For those of ordinary skill in the art, not Under the premise of being detached from the invention design, various modifications and improvements can be made, these belong to the protection model of the present invention It encloses.

Claims (4)

1. a kind of drug for preventing and/or treating Parkinson's disease, which is characterized in that its active ingredient is by following parts by weight object Matter forms：8~15 parts by weight of curcuma zedoary, 15~25 parts by weight of Glabrous Sarcandra Herb, 15~25 parts by weight of Asian puccoon, 10~20 parts by weight of radix paeoniae rubra, 15~25 parts by weight of smilax, 15~25 parts by weight of dark plum, 15~25 parts by weight of Radix Glycyrrhizae, 15~25 parts by weight of Radix Angelicae Sinensis, Rhizoma Chuanxiong 15 ~25 parts by weight, 15~25 parts by weight of Radix Rehmanniae.
2. according to claim 1 for preventing and/or treating the drug of Parkinson's disease, which is characterized in that its effectively at Divide by following parts by weight material composition：10 parts by weight of curcuma zedoary, 20 parts by weight of Glabrous Sarcandra Herb, 20 parts by weight of Asian puccoon, 15 parts by weight of radix paeoniae rubra, 20 parts by weight of smilax, 20 parts by weight of dark plum, 10 parts by weight of Radix Glycyrrhizae, 10 parts by weight of Radix Angelicae Sinensis, 10 parts by weight of Rhizoma Chuanxiong, 20 weight of Radix Rehmanniae Part.
3. the preparation method of drug as claimed in claim 1 or 2, which is characterized in that include the following steps：
(1) it weighs smilax and crushed 80 mesh sieve, it is spare；
(2) curcuma zedoary, Glabrous Sarcandra Herb, Asian puccoon, radix paeoniae rubra, dark plum, Radix Glycyrrhizae, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Rehmanniae drying medicine materical crude slice are weighed, is decocted with water extraction It boils three times, for the first time plus 10~12 times are measured water, are extracted 2 hours；Second and third time is respectively plus 8~10 times are measured water, extracts 1 hour, mistake Filter merges extracting solution, discards residue；
(3) it is concentrated under reduced pressure into heat and surveys the thick paste that proportion is 1.10~1.20, be cooled to room temperature, addition ethyl alcohol to alcohol content 70%, It places for 24 hours, filtering, recycles ethyl alcohol, concentration stops heat and surveys the thick paste that proportion is 1.30~1.40；
(4) it takes lactose, starch, dextrin to be uniformly mixed with the thick paste of step (3), dry, pulverize 80 mesh sieve, magnesium stearate is added With the smilax powder of step (1), it is uniformly mixed, conventionally prepares piece agent；Wherein, the lactose, starch and dextrin Addition be the 32.67% of thick paste weight, weight ratio between lactose, starch and dextrin is 1:2:6, the magnesium stearate Addition is the 0.67% of thick paste weight.
4. drug as claimed in claim 1 or 2 is preparing the application in preventing and/or treating the drug of Parkinson's disease disease.
CN201810366621.XA 2018-04-23 2018-04-23 Drug and preparation method thereof for preventing and/or treating Parkinson's disease Pending CN108498756A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810366621.XA CN108498756A (en) 2018-04-23 2018-04-23 Drug and preparation method thereof for preventing and/or treating Parkinson's disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810366621.XA CN108498756A (en) 2018-04-23 2018-04-23 Drug and preparation method thereof for preventing and/or treating Parkinson's disease

Publications (1)

Publication Number Publication Date
CN108498756A true CN108498756A (en) 2018-09-07

Family

ID=63383043

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810366621.XA Pending CN108498756A (en) 2018-04-23 2018-04-23 Drug and preparation method thereof for preventing and/or treating Parkinson's disease

Country Status (1)

Country Link
CN (1) CN108498756A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103239598A (en) * 2012-02-13 2013-08-14 杨明会 Traditional Chinese medicine composition for treatment of Parkinson's disease and application thereof
CN105233150A (en) * 2015-09-29 2016-01-13 广东省中医院 Traditional Chinese medicine composition and application thereof
CN105749159A (en) * 2016-03-29 2016-07-13 南方医科大学 Application of traditional Chinese medicine for treating psoriasis in preparation of medicine for treating multiple sclerosis
CN107648482A (en) * 2017-11-10 2018-02-02 广东省中医院 A kind of Chinese medicine composition for being used to treat nerve degenerative diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103239598A (en) * 2012-02-13 2013-08-14 杨明会 Traditional Chinese medicine composition for treatment of Parkinson's disease and application thereof
CN105233150A (en) * 2015-09-29 2016-01-13 广东省中医院 Traditional Chinese medicine composition and application thereof
CN105749159A (en) * 2016-03-29 2016-07-13 南方医科大学 Application of traditional Chinese medicine for treating psoriasis in preparation of medicine for treating multiple sclerosis
CN107648482A (en) * 2017-11-10 2018-02-02 广东省中医院 A kind of Chinese medicine composition for being used to treat nerve degenerative diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
宋秋云: "帕金森综合征从痰从瘀论治", 《浙江中西医结合杂志》 *

Similar Documents

Publication Publication Date Title
CN105920476B (en) Traditional Chinese medicine composition for preventing and treating Alzheimer disease and preparation method thereof
CN101862374A (en) Lotus plumule and new application of extractive thereof
CN103071048A (en) Traditional Chinese medicine composition for treating alzheimer diseases and preparation method of traditional Chinese medicine composition
Ma et al. Naoxintong protects primary neurons from oxygen‐glucose deprivation/reoxygenation induced injury through PI3K‐Akt signaling pathway
KR20140147948A (en) Manufacturing Method for Allomyrina dichotoma extract having anti-Obesity effect and Anti-Obesity Composition Containing the same
CN108524814A (en) A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose
CN103720959B (en) Parkinsonian pharmaceutical composition of a kind of preventing and treating and preparation method thereof
CN108403723B (en) A kind of American-cockroach-extract that intervening AD and its extracting method and application
Xu et al. Efficacy of curculigoside in protecting against ischemic brain injury through regulation of oxidative stress and NF-κB and PI3K/Akt expression
CN106138210A (en) Butterflybush flower and the application of the medicine as preparation treatment hypertensive cardiopathy for the extract thereof
Zhang et al. Research progress in the effect of traditional Chinese medicine for invigoration on neurotransmitter related diseases
CN108310298A (en) It is a kind of that there is the Chinese medicine composition and preparation method for alleviating asthenopia, prevention myopia
CN112190512A (en) Preparation method and application of eye cream with remarkable curative effect on dark eye circles and under-eye puffiness
Raja et al. Randomized trial on weight and lipid profile of obese by formulation from Garcina cambogia
CN103977390B (en) A kind of preparation method and its usage of ginger onion medicated wine composition
El-Khatib et al. Over-the-Counter Supplements and Men's Health
CN103108639A (en) Composition of active ingredient of traditional chinese medicine and use thereof
CN108498756A (en) Drug and preparation method thereof for preventing and/or treating Parkinson's disease
CN105919111A (en) Fruit enzyme and preparation method thereof
CA2976896A1 (en) Water extracts of cinnamon and radix astragali
CN101972334A (en) Traditional Chinese medicine preparation for preventing and treating infantile eczema and preparation method thereof
CN108567914A (en) It is a kind of that there is the Chinese medicine preparation and its preparation method and application for improving sleep effect
CN102934799A (en) Healthcare product containing broad bean extracts and application of healthcare product
CN105999082A (en) Formula applicable to patients with hepatitis liver cirrhosis at decompensated stage and accompanied hepatic encephalopathy of hepatitis liver cirrhosis
Amare et al. Evaluation of antidiabetic and antidyslipidemic effects of methanolic extract of Pentas Schimperiana leaf in mice

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180907

RJ01 Rejection of invention patent application after publication